09.10.10
Averion, Trio Clinical Research, Fulcrum Pharma and ClinResearch/ADDPLAN have merged into a new global biopharmaceutical and medical device development services organization. The merger, led by a group of investors including The Halifax Group, SV Life Sciences and the Comvest Group, is part of a strategy to address the pressures and challenges currently facing the pharmaceutical, biotech, and medical device industry through an integrated service offering.
Patrick K. Donnelly, formerly the chief executive officer and one of the founders of PRA International, was named chairman and chief executive officer of the new group and J. Matthew Bond, also from PRA, joins as the chief financial officer.
“With this new financial partnership and the combination of services from each company, we can now offer clients around the world access to over 800 professionals that can provide innovative, comprehensive and proven development capabilities. The drug and device industry needs to approach development from a different and more dynamic paradigm,” said Mr. Donnelly.
Patrick K. Donnelly, formerly the chief executive officer and one of the founders of PRA International, was named chairman and chief executive officer of the new group and J. Matthew Bond, also from PRA, joins as the chief financial officer.
“With this new financial partnership and the combination of services from each company, we can now offer clients around the world access to over 800 professionals that can provide innovative, comprehensive and proven development capabilities. The drug and device industry needs to approach development from a different and more dynamic paradigm,” said Mr. Donnelly.